ArticleFuture microbiology2012
Unraveling the structural basis of HIV-1 neutralization.
Article in Future microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.Current HIV research · 2018Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Evaluation of: Tran EE, Borgnia MJ, Kybeda O et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 8(7), e1002797 (2012). New breakthroughs are needed in the ongoing struggle to develop an effective HIV vaccine. Chief among the challenges to obtaining an effective vaccine is the remarkable ability of the virus to evade humoral immune responses that arise in the infected host. Understanding how broadly neutralizing antibodies directed against the trimeric envelope glycoprotein of HIV (Env) work to overcome viral defenses is, therefore, a high priority. Tran and colleagues used high-resolution 3D cryoelectron tomography to define the conformation of Env when bound to soluble CD4 and to a series of monoclonal antibodies. The investigators demonstrate that antibodies binding to the CD4 binding site or coreceptor binding site of Env may lead to significantly different conformations of the trimeric Env complex. Remarkably, the broadly neutralizing antibody VRC01 locks the complex in a closed conformation, while binding to soluble CD4 or the monoclonal antibody 17b fixed the trimer in an open conformation. Furthermore, these investigators were able to define a new open conformation of the N-terminal region of the gp41 transmembrane protein, which is proposed to be a new structural intermediate occurring after receptor engagement. These findings may aid in the design of immunogens that can generate broadly neutralizing antibodies against HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.